AstraZeneca highlights its impact on the UK economy
Anglo-Swedish drug major AstraZeneca is improving the UK's wealth as well as health, according to an economic report the firm commissioned to establish its net worth. The Economic Contribution of AstraZeneca to the UK and Its Regions - based on the latest available economic data - reveals that, in 2004, the firm's UK operations added over L2.5 billion ($5.0 billion) to the bottom line of "UK plc."
According to the report, the UK is a core part of AstraZeneca's worldwide operations, as it is home to the company's corporate headquarters, major R&D facilities, manufacturing sites and business support functions.
In 2004, investment by AstraZeneca in its UK-based operations:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze